- Home
- LYEL vs LRMR Comparison
LYEL vs LRMR Comparison
Compare LYEL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- LRMR
- Stock Information
- Founded
- LYEL 2018
- LRMR N/A
- Country
- LYEL United States
- LRMR United States
- Employees
- LYEL N/A
- LRMR N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- LRMR Health Care
- Exchange
- LYEL Nasdaq
- LRMR Nasdaq
- Market Cap
- LYEL 207.7M
- LRMR 183.8M
- IPO Year
- LYEL 2021
- LRMR N/A
- Fundamental
- Price
- LYEL $0.43
- LRMR $1.91
- Analyst Decision
- LYEL Sell
- LRMR Strong Buy
- Analyst Count
- LYEL 2
- LRMR 9
- Target Price
- LYEL $1.00
- LRMR $19.00
- AVG Volume (30 Days)
- LYEL 752.1K
- LRMR 1.0M
- Earning Date
- LYEL 05-05-2025
- LRMR 05-08-2025
- Dividend Yield
- LYEL N/A
- LRMR N/A
- EPS Growth
- LYEL N/A
- LRMR N/A
- EPS
- LYEL N/A
- LRMR N/A
- Revenue
- LYEL $61,000.00
- LRMR N/A
- Revenue This Year
- LYEL N/A
- LRMR N/A
- Revenue Next Year
- LYEL N/A
- LRMR N/A
- P/E Ratio
- LYEL N/A
- LRMR N/A
- Revenue Growth
- LYEL N/A
- LRMR N/A
- 52 Week Low
- LYEL $0.39
- LRMR $1.61
- 52 Week High
- LYEL $2.88
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- LYEL 39.54
- LRMR 39.39
- Support Level
- LYEL $0.43
- LRMR $1.76
- Resistance Level
- LYEL $0.51
- LRMR $1.91
- Average True Range (ATR)
- LYEL 0.05
- LRMR 0.17
- MACD
- LYEL 0.00
- LRMR 0.03
- Stochastic Oscillator
- LYEL 23.43
- LRMR 46.15
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.